EuroBiotech Report: GSK spinout raises £23M, Tiziana gets drug for NASH combo and Protalix posts phase 2 CF data

europeGOOD

Welcome to the first EuroBiotech Report of 2017. We start this shortened edition in Britain, where GlaxoSmithKline spinout NeRRe Therapeutics raised £23 million ($28 million). The cash will allow NeRRe to take two neurokinin receptor antagonists to phase 2 data readouts. Fellow British biotech Tiziana Life Sciences was also in the news. Tiziana started 2017 by licensing an anti-interleukin-6 receptor drug from Novimmune that it sees as complementary to its existing NASH candidate. Protalix BioTherapeutics posted an interim look at data from a phase 2 trial of its cystic fibrosis candidate. And more. Nick Taylor

1. GSK spinout bags £23M to take NK antagonists into phase 2

NeRRe Therapeutics has raised £23 million ($28 million) in a Series B backed by new investors Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed. The GlaxoSmithKline spinout will use the money to take two neurokinin receptor antagonists to phase 2 data readouts.

Featured Whitepaper

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

2. Tiziana plots NASH combo after buying Novimmune asset

Tiziana Life Sciences has licensed an anti-interleukin-6 receptor (IL-6R) drug from Novimmune. The British biotech sees the monoclonal antibody as complementary to foralumab, a NASH candidate it picked up from Novimmune two years ago.

3. Protalix talks up CF prospects in interim phase 2 data drop

Protalix BioTherapeutics has posted an interim look at data from a small phase 2 trial of its cystic fibrosis candidate. The Israeli biotech used the update to talk up areas in which the data compare favorably to results generated by Vertex Pharmaceuticals’ CFTR modulator on its path to approval.

And more articles of note>>

Suggested Articles

Novo is working on a once-weekly basal insulin that could cut down on injections for people with Type 2 diabetes, and the phase 2 data look promising.

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.